ArticleBMC cancer2024
Long-term relative survival of patients with gastric cancer from a large-scale cohort: a period-analysis.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Prognostic Value of albumin-bilirubin (ALBI) Grade in Patients with Gastric Cancer: A Systematic Review and meta-analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Serum markers and gastric cancer: an umbrella review.BMC gastroenterology · 2025Pooled it
- Postoperative Complications and Long-Term Cardiovascular Risk After Gastrectomy for Gastric Cancer.Annals of surgical oncology · 2026Article
- Impact of Socioeconomic Status on Early Gastric Cancer Outcomes and Treatment Disparity: a SEER analysis.Journal of gastrointestinal cancer · 2026Article
- Article
- Circulating miRNA-30a is associated with favorable therapeutic outcome in patients with gastric cancer treated with neoadjuvant chemotherapy.Oncology letters · 2026Article
- Prognostic significance and tumor cell interactions of tumor-associated neutrophils in gastric cancer.Molecular medicine (Cambridge, Mass.) · 2026Article
- The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer.Oncology letters · 2026Article
- Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients.Cancer biology & medicine · 2026Review
- cGAS-STING Pathway in Gastrointestinal Malignancies: Mechanistic Insights and Translational Therapeutic Opportunities.Journal of gastrointestinal cancer · 2026Review
- Learning from an Emerging Infection: How the COVID-19 Pandemic Reshaped Gastric Cancer Care.Life (Basel, Switzerland) · 2026Review
- Optimized CNN framework with VGG19, EfficientNet, and Bayesian optimization for early colon cancer detection.Scientific reports · 2026Article
- Characterization of the gastric mucosal microbiota in tumoral and peritumoral mucosa in patients with advanced gastric cancer from Northwest China.Frontiers in microbiology · 2026Article
- Molecular and structural reprogramming of gastric cancer revealed by systems-level transcriptomic analysis.PloS one · 2026Article
- Multidimensional decision support by artificial intelligence across the full workflow of endoscopic submucosal dissection for early gastric cancer.Frontiers in oncology · 2026Review
- Estimated five-year survival and direct healthcare costs of adult patients with gastric cancer: real-world evidence from a tertiary hospital in Colombia.Frontiers in public health · 2026Article
- Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGastric cancer poses a significant global health challenge. We aim to use period analysis to assess the changes in gastric cancer treatment at our center over the past 15 years. This study reflects the current state of gastric cancer treatment at our center and provides valuable data to support clinical advancements.
methodWe used period analysis to evaluate the survival status of 3915 patients with gastric cancer at Nanfang Hospital, Southern Medical University, over a 15-year period spaning from 2008 to 2022. The 5-year relative survival rates were analyzed.
resultOur findings indicate that the 5-year relative survival rate at our center from 2018 to 2022 is 71.4%. From 2018 to 2022, the 5-year relative survival rates for patients aged < 40, 40-54, 55-69, and ≥ 70 reached 67.5%, 73.5%, 72.0%, and 67.1%, respectively. For stage IV patients, the 5-year relative survival rate reached 29% in 2018-2022. For stage I-III patients, the 5-year relative survival rate reached 89.7% in 2018-2022. The five-year relative survival rate for patients who underwent laparoscopic surgery at our center rose from 50.3% in 2008-2012 to 71.4% in 2018-2022. Overall, there has been a notable increase in the 5-year relative survival rates, regardless of age, gender, region, or tumor stage.
conclusionPeriod analysis over the past 15 years shows significant improvement in the 5-year survival rate for gastric cancer at our center. This progress is due to standardized surgical techniques, perioperative management, and immunotherapy, providing robust data for evaluating the efficacy of recent treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.